密度	1.232

没有数据	没有数据

来源	SDS样本
没有数据	没有数据

产品合成路线

更多

名称	CAS号

更多

文章

同行评议文献

Montanide ISA 720 and 51: a new generation of water in oil emulsions as adjuvants for human vaccines.Jerome Aucouturier et al.Expert review of vaccines, 1(1), 111-118 (2003-08-12) Immunization with analog peptide in combination with CpG and montanide expands tumor antigen-specific CD8+ T cells in melanoma patients.Julien Fourcade et al.Journal of immunotherapy (Hagerstown, Md. : 1997), 31(8), 781-791 (2008-09-10) Preclinical vaccine study of Plasmodium vivax circumsporozoite protein derived-synthetic polypeptides formulated in montanide ISA 720 and montanide ISA 51 adjuvants.Myriam Arévalo-Herrera et al.The American journal of tropical medicine and hygiene, 84(2 Suppl), 21-27 (2011-02-15) Adjuvants for enhancing the immunogenicity of whole tumor cell vaccines.Cheryl Lai-Lai Chiang et al.International reviews of immunology, 30(2-3), 150-182 (2011-05-12) Characterization of blood-brain barrier integrity in a B-cell-dependent mouse model of multiple sclerosis.Luisa Bell et al.Histochemistry and cell biology, 151(6), 489-499 (2019-01-23) Immunogenicity of the Plasmodium falciparum Pf332-DBL domain in combination with different adjuvants.Cheng Du et al.Vaccine, 28(31), 4977-4983 (2010-07-24) Phase I safety and immunogenicity trial of Plasmodium vivax CS derived long synthetic peptides adjuvanted with montanide ISA 720 or montanide ISA 51.Sócrates Herrera et al.The American journal of tropical medicine and hygiene, 84(2 Suppl), 12-20 (2011-02-15) A phase 1 trial of MSP2-C1, a blood-stage malaria vaccine containing 2 isoforms of MSP2 formulated with Montanide® ISA 720.James S McCarthy et al.PloS one, 6(9), e24413-e24413 (2011-09-29) Comparative Immunogenicities of full-length Plasmodium falciparum merozoite surface protein 3 and a 24-kilodalton N-terminal fragment.Maryam Imam et al.Clinical and vaccine immunology : CVI, 18(8), 1221-1228 (2011-06-03) Safety and immunogenicity of a recombinant Plasmodium falciparum AMA1 malaria vaccine adjuvanted with Alhydrogel, Montanide ISA 720 or AS02.Meta Roestenberg et al.PloS one, 3(12), e3960-e3960 (2008-12-19) Phase 1 safety and immunogenicity trial of the Plasmodium falciparum blood-stage malaria vaccine AMA1-C1/ISA 720 in Australian adults.Mark A Pierce et al.Vaccine, 28(10), 2236-2242 (2010-01-07) Pichia pastoris-expressed dengue virus type 2 envelope domain III elicits virus-neutralizing antibodies.Gaurav Batra et al.Journal of virological methods, 167(1), 10-16 (2010-03-10) Thermal nociception and TRPV1 function are attenuated in mice lacking the nucleotide receptor P2Y2.Sacha A Malin et al.Pain, 138(3), 484-496 (2008-03-18) Long term stability of a recombinant Plasmodium falciparum AMA1 malaria vaccine adjuvanted with Montanide(®) ISA 720 and stabilized with glycine.Daming Zhu et al.Vaccine, 29(20), 3640-3645 (2011-03-29) Preformulation studies on Freund's incomplete adjuvant emulsion.R O Williams et al.Drug development and industrial pharmacy, 24(2), 157-162 (2004-12-21) Comparison of the adjuvanticity of two different delivery systems on the induction of humoral and cellular responses to synthetic peptides.Elena Mata et al.Drug delivery, 17(7), 490-499 (2010-05-27) Effects on immunogenicity by formulations of emulsion-based adjuvants for malaria vaccines.Christopher B Fox et al.Clinical and vaccine immunology : CVI, 19(10), 1633-1640 (2012-08-17) Long-term humoral and cellular immune responses elicited by a heterologous Plasmodium vivax apical membrane antigen 1 protein prime/adenovirus boost immunization protocol.Leoneide Érica Maduro Bouillet et al.Infection and immunity, 79(9), 3642-3652 (2011-07-07) Vaccination with recombinant Plasmodium vivax MSP-10 formulated in different adjuvants induces strong immunogenicity but no protection.Manuel A Giraldo et al.Vaccine, 28(1), 7-13 (2009-09-29) Identification of potent biodegradable adjuvants that efficiently break self-tolerance--a key issue in the development of therapeutic vaccines.Maria Ringvall et al.Vaccine, 28(1), 48-52 (2009-10-20) Evaluation of phenoxybenzamine in the CFA model of pain following gene expression studies and connectivity mapping.Meiping Chang et al.Molecular pain, 6, 56-56 (2010-09-18) Protection against an intranasal challenge by vaccines formulated with native and recombinant preparations of the Chlamydia trachomatis major outer membrane protein.Guifeng Sun et al.Vaccine, 27(36), 5020-5025 (2009-05-19) Immunization with pre-erythrocytic antigen CelTOS from Plasmodium falciparum elicits cross-species protection against heterologous challenge with Plasmodium berghei.Elke S Bergmann-Leitner et al.PloS one, 5(8), e12294-e12294 (2010-09-03) Nimodipine fosters remyelination in a mouse model of multiple sclerosis and induces microglia-specific apoptosis.Andrea Schampel et al.Proceedings of the National Academy of Sciences of the United States of America, 114(16), E3295-E3304 (2017-04-07) Immunization with Leishmania vaccine-alum-BCG and montanide ISA 720 adjuvants induces low-grade type 2 cytokines and high levels of IgG2 subclass antibodies in the vervet monkey (Chlorocebus aethiops) model.J M Mutiso et al.Scandinavian journal of immunology, 76(5), 471-477 (2012-08-07) Stability and potency of the Plasmodium falciparum MSP1-19/AMA-1(III) chimeric vaccine candidate with Montanide ISA720 adjuvant.Xiangyang Xue et al.Vaccine, 28(18), 3152-3158 (2010-03-04) CpG oligodeoxynucleotide and montanide ISA 206 adjuvant combination augments the immune responses of a recombinant FMDV vaccine in cattle.Jiling Ren et al.Vaccine, 29(45), 7960-7965 (2011-08-30) Immunogenicity of a virosomally-formulated Plasmodium falciparum GLURP-MSP3 chimeric protein-based malaria vaccine candidate in comparison to adjuvanted formulations.Marco Tamborrini et al.Malaria journal, 10, 359-359 (2011-12-15) Tailoring subunit vaccine immunogenicity: maximizing antibody and T cell responses by using combinations of adenovirus, poxvirus and protein-adjuvant vaccines against Plasmodium falciparum MSP1.Alexander D Douglas et al.Vaccine, 28(44), 7167-7178 (2010-10-13) Metabolic fate of mineral oil adjuvants using 14C-labeled tracers. II. Mannide monooleate.J N Bollinger Journal of pharmaceutical sciences, 59(8), 1088-1092 (1970-08-01)

备注